IL316891A - BRM-targeted compounds and related methods of use - Google Patents
BRM-targeted compounds and related methods of useInfo
- Publication number
- IL316891A IL316891A IL316891A IL31689124A IL316891A IL 316891 A IL316891 A IL 316891A IL 316891 A IL316891 A IL 316891A IL 31689124 A IL31689124 A IL 31689124A IL 316891 A IL316891 A IL 316891A
- Authority
- IL
- Israel
- Prior art keywords
- associated methods
- targeting compounds
- brm
- brm targeting
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340185P | 2022-05-10 | 2022-05-10 | |
| PCT/US2023/066755 WO2023220577A1 (en) | 2022-05-10 | 2023-05-09 | 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 protein degraders for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316891A true IL316891A (en) | 2025-01-01 |
Family
ID=86771366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316891A IL316891A (en) | 2022-05-10 | 2023-05-09 | BRM-targeted compounds and related methods of use |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230365576A1 (enExample) |
| EP (1) | EP4522621A1 (enExample) |
| JP (1) | JP2025521091A (enExample) |
| KR (1) | KR20250011136A (enExample) |
| CN (1) | CN119487036A (enExample) |
| AU (1) | AU2023269778A1 (enExample) |
| CA (1) | CA3252552A1 (enExample) |
| IL (1) | IL316891A (enExample) |
| MX (1) | MX2024013843A (enExample) |
| WO (1) | WO2023220577A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023549341A (ja) * | 2020-11-06 | 2023-11-24 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
| WO2024208300A1 (zh) * | 2023-04-07 | 2024-10-10 | 南京再明医药有限公司 | Brm选择性降解剂化合物 |
| WO2025106472A1 (en) * | 2023-11-13 | 2025-05-22 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2025113460A1 (zh) * | 2023-11-28 | 2025-06-05 | 西藏海思科制药有限公司 | 一种哒嗪并三环衍生物及其在医药上的应用 |
| WO2025193454A1 (en) | 2024-03-01 | 2025-09-18 | Prelude Therapeutics Incorporated | Brm and brg1 targeting antibody-drug conjugates and methods of use thereof |
| WO2026090411A1 (en) | 2024-10-23 | 2026-04-30 | Prelude Therapeutics Incorporated | Brm and brg1 targeting compounds and associated methods of use |
| CN119504710B (zh) * | 2024-11-18 | 2025-10-17 | 昆明医科大学 | 靶向降解PRMT5的PROTACs化合物及其应用 |
| CN121873038A (zh) * | 2026-03-16 | 2026-04-17 | 南开大学 | 针对结直肠癌的靶向蛋白水解嵌合体及其制备方法、药物组合物和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP2023529908A (ja) * | 2020-06-09 | 2023-07-12 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
| JP2023549341A (ja) * | 2020-11-06 | 2023-11-24 | プレリュード・セラピューティクス・インコーポレイテッド | Ｂｒｍ標的化化合物及び関連する使用方法 |
-
2023
- 2023-05-09 WO PCT/US2023/066755 patent/WO2023220577A1/en not_active Ceased
- 2023-05-09 CN CN202380048631.8A patent/CN119487036A/zh active Pending
- 2023-05-09 IL IL316891A patent/IL316891A/en unknown
- 2023-05-09 CA CA3252552A patent/CA3252552A1/en active Pending
- 2023-05-09 US US18/314,190 patent/US20230365576A1/en active Pending
- 2023-05-09 KR KR1020247040958A patent/KR20250011136A/ko active Pending
- 2023-05-09 JP JP2024566379A patent/JP2025521091A/ja active Pending
- 2023-05-09 AU AU2023269778A patent/AU2023269778A1/en active Pending
- 2023-05-09 EP EP23731058.6A patent/EP4522621A1/en active Pending
-
2024
- 2024-11-08 MX MX2024013843A patent/MX2024013843A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20250011136A (ko) | 2025-01-21 |
| JP2025521091A (ja) | 2025-07-08 |
| WO2023220577A1 (en) | 2023-11-16 |
| MX2024013843A (es) | 2025-02-10 |
| CA3252552A1 (en) | 2023-11-16 |
| CN119487036A (zh) | 2025-02-18 |
| AU2023269778A1 (en) | 2024-12-12 |
| US20230365576A1 (en) | 2023-11-16 |
| EP4522621A1 (en) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298933B1 (en) | BRM-targeted compounds and related methods of use | |
| IL319545A (en) | BRM-targeted compounds and related methods of use | |
| IL320864A (en) | BRM-targeted compounds and related methods of use | |
| IL277677A (en) | BRM-targeted compounds and related methods of use | |
| IL299167A (en) | Compositions and methods for treating patients with gene therapy | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| GB2616795B (en) | Compositions and methods for the targeting of BCL11A | |
| IL314320A (en) | Compounds and methods of use | |
| IL286697A (en) | Neurogulin-4 compounds and methods of use | |
| IL318209A (en) | Medical compounds and methods | |
| IL318393A (en) | Azaquinazoline compounds and methods of use | |
| GB202410580D0 (en) | Nanoantibody b12 targeting ceacam5 and use of nanoantibody b12 | |
| IL317018A (en) | Garden treatment preparations and methods of using them | |
| IL314277A (en) | Anti-B7-H3 compounds and methods of use | |
| IL309878A (en) | Therapeutic compounds and methods | |
| ZA202108165B (en) | Application of kdm5a gene and atrx gene | |
| GB202119051D0 (en) | Wingsail and method of use | |
| CA3273531A1 (en) | Brm targeting compounds and associated methods of use | |
| HK40130022A (en) | Brm targeting compounds and associated methods of use | |
| HK40101161A (en) | Brm targeting compounds and associated methods of use | |
| HK40095345A (en) | Brm targeting compounds and associated methods of use | |
| IL308533A (en) | Compounds and methods targeting epirgoline | |
| IL318499A (en) | Compounds for targeted lysosomal degradation and methods of using them | |
| IL304191A (en) | elagolix administration methods | |
| HK40076335A (en) | Brm targeting compounds and associated methods of use |